Reverting Tumor Invisibility: Targeting the Epigenetic Axis in Genome-Doubled Cancers

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Cancer Cell  https://doi.org/10.1016/j.ccell.2026.04.007 
Dr. Pierre Foidart et al.

Points

Whole-genome doubling occurs in approximately 37 percent of primary solid tumors and up to 56 percent of metastatic cases and is consistently linked to poor clinical outcomes and resistance.
Tumor cells with doubled genomes initially attract immune attention but eventually achieve invisibility by switching off the genes responsible for producing major histocompatibility complex class I proteins for antigen presentation.
This immune evasion is driven by epigenetic silencing through the PRC2 complex which is triggered by increased succinate levels and metabolic alterations that modify the DNA expression without changing sequences.
Research demonstrates that pharmacologically targeting the PRC2 complex can successfully restore antigen presentation and enhance the infiltration of cytotoxic CD8+ T lymphocytes to make tumor cells recognizable to the immune system.
Identifying whole-genome doubling as a biomarker may allow doctors to stratify patients for specialized treatment combinations involving epigenetic inhibitors and immunotherapy to effectively target and suppress metastatic growth.

Summary

Whole-genome doubling (WGD) is a prevalent macro-evolutionary event in oncology, occurring in approximately 37% of primary solid tumors and increasing to 56% in metastatic disease. While historically associated with genomic instability and poor prognosis, this study elucidates a metabolic-epigenetic axis that drives immune evasion following WGD. Using mouse mammary tumor models and single-cell profiling, researchers identified that while WGD initially increases tumor visibility, the cells rapidly undergo a transcriptomic shift. This transition is characterized by reduced response to interferon-gamma (IFN-γ) and the silencing of major histocompatibility complex class I (MHC-I) transcriptional regulators, effectively rendering the cells “invisible” to cytotoxic CD8+ T lymphocytes.

Mechanistically, the study reveals that WGD+ tumors exhibit elevated levels of succinate and decreased KDM6 activity, which subsequently increases histone H3 lysine 27 trimethylation (H3K27me3). This epigenetic landscape is maintained by the Polycomb Repressive Complex 2 (PRC2), which facilitates the transcriptional repression of essential immune genes. Unlike fixed genetic mutations, these modifications are reversible. Pharmacological interventions targeting the PRC2 complex or utilizing the BIRC5 inhibitor YM155 were shown to preferentially suppress WGD+ tumor growth, restore MHC-I antigen presentation, and enhance CD8+ T cell infiltration, suggesting a strategy to overcome treatment resistance.

These findings suggest that WGD status serves as a critical biomarker for patient stratification in breast cancer and other solid tumors. Although WGD+ cells evade baseline immune surveillance, their epigenetic profile may render them more sensitive to anti-PD-L1 therapies when combined with epigenetic modulators. The research highlights the potential for combining PRC2 inhibitors with immunotherapy to reactivate the anti-tumor immune response. Future clinical studies are warranted to validate these combined therapeutic approaches and to develop cost-effective methods for detecting WGD in routine pathology, moving beyond the current constraints of high-cost whole-genome sequencing.

Link to the article: https://www.sciencedirect.com/science/article/pii/S1535610826002187?via%3Dihub

References

Foidart, P., Li, Z., Cai, X., Seehawer, M., Brown, D. D., Tawawalla, A., Baldominos, P., Parvin, S., Nishida, J., Rojas-Jimenez, E., Bui, T. M., Diciaccio, B., Kumar, R., Schlegel, B. T., Goyette, M.-A., Scales, T., Yan, P., Qiu, X., Li, R., … Polyak, K. (2026). Whole-genome doubling drives immune evasion by silencing antigen presentation. Cancer Cell, S1535610826002187. https://doi.org/10.1016/j.ccell.2026.04.007